Bayer Surges After Earnings Beat Estimates on New Drug Sales (4)

Bayer AG’s shares surged after its earnings beat expectations, with robust demand for its new cancer and kidney medicines helping offset a decline in agricultural sales.

Adjusted earnings came in at €4.09 billion ($4.54 billion) before interest, taxes, depreciation and amortization, according to a statement Tuesday. That result, a 7.4% drop from a year earlier, outpaced the average analyst estimate of €3.88 billion.

The company’s shares jumped more than 11% in early trading. The stock is still down roughly 9% over the past year.

Bayer confirmed its 2025 outlook, though it noted that there’s considerable uncertainty around tariffs and ...